SBIR-STTR Award

OptoAcoustic and Ultrasonic Imaging of Angiogenesis
Award last edited on: 12/11/07

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$1,443,982
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Walter G Scott

Company Information

UltraVision Corporation (AKA: Winprobe Corporation)

11911 US Highway 1 Suite 204
North Palm Beach, FL 33408
   (561) 626-4405
   info@winprobe.com
   www.winprobe.com
Location: Single
Congr. District: 18
County: Palm Beach

Phase I

Contract Number: 1R44CA110079-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2004
Phase I Amount
$97,158
This proposal for "Optoacoustic and Ultrasonic Imaging of Angiogenesis" combines optoacoustics and ultrasound in a single instrument for the first time. A I 2MHz phased array ultrasound probe equipped with fiber optics for delivery of laser illuminations will operate in the backwards mode. In this method the ultrasonic image and the optoacoustic image will be spatially overlaid and then fused in some presentations. The ultrasonic images will include B-Mode, color Flow Doppler, power Doppler and Spectral Doppler. A stacked transducer will double the acoustic spectral capabilities to 24 MHz on reception to attain visualization of very small vessels in the neovascuIarization. An OPO laser will provide a narrow wavelength from a spectrum of Infra Red wavelengths of light to photometrically select different compounds for light absorption, expansion and emission of ultrasound. Estimation of the oxy / deoxy hemoglobin in small vascular regions will be displayed as an image overlay. This unique instrument differentiates blood in optoacoustics, and tissue in ultrasound, allowing very high resolution of blood vessels, their flow (especially low flow without interference of wall motion) and their oxygen content. WinProbe's Scientific Research Platform will be optimized for this new combination of modalities and will produce fused images in real time. This proposal includes clinical studies to image and quantitatively access angiogenesis in mice under the effect of known anti-angiogenesis drugs. The goal is to commercialize an instrument for clinical research. The role of angiogenesis in cancer is well documented in the literature and this instrument can be expected to make a significant contribution to the science of cancer research. Future commercial products are expected to follow in endoscopic instruments to assist in the detection of cancer where optical assessments are limited to the surface and are contrast deprived

Phase II

Contract Number: 4R44CA110079-02
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
2005
(last award dollars: 2007)
Phase II Amount
$1,346,824

This proposal for "Optoacoustic and Ultrasonic Imaging of Angiogenesis" combines optoacoustics and ultrasound in a single instrument for the first time. A I 2MHz phased array ultrasound probe equipped with fiber optics for delivery of laser illuminations will operate in the backwards mode. In this method the ultrasonic image and the optoacoustic image will be spatially overlaid and then fused in some presentations. The ultrasonic images will include B-Mode, color Flow Doppler, power Doppler and Spectral Doppler. A stacked transducer will double the acoustic spectral capabilities to 24 MHz on reception to attain visualization of very small vessels in the neovascuIarization. An OPO laser will provide a narrow wavelength from a spectrum of Infra Red wavelengths of light to photometrically select different compounds for light absorption, expansion and emission of ultrasound. Estimation of the oxy / deoxy hemoglobin in small vascular regions will be displayed as an image overlay. This unique instrument differentiates blood in optoacoustics, and tissue in ultrasound, allowing very high resolution of blood vessels, their flow (especially low flow without interference of wall motion) and their oxygen content. WinProbe's Scientific Research Platform will be optimized for this new combination of modalities and will produce fused images in real time. This proposal includes clinical studies to image and quantitatively access angiogenesis in mice under the effect of known anti-angiogenesis drugs. The goal is to commercialize an instrument for clinical research. The role of angiogenesis in cancer is well documented in the literature and this instrument can be expected to make a significant contribution to the science of cancer research. Future commercial products are expected to follow in endoscopic instruments to assist in the detection of cancer where optical assessments are limited to the surface and are contrast deprived.

Thesaurus Terms:
angiocardioultrasonography, angiogenesis, biomedical equipment development, fiber optics, image processing angiogenesis inhibitor, laser, light scattering, oxyhemoglobin, phantom model bioimaging /biomedical imaging, laboratory mouse